Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.
Feasby
T E
TE
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy; D007958:Leukocyte Count / Q000187:drug effects; D008212:Lymphocyte Depletion; D008297:Male; D016853:Muromonab-CD3; D009460:Neurologic Examination; D011129:Polyradiculoneuropathy / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3